SENS PubMed Publication Search
Intranasal administration of trehalose reduces α-synuclein oligomers and accelerates α-synuclein aggregation
Brain Commun. 2024 Aug 20;6(4):fcae193. doi: 10.1093/braincomms/fcae193.
Makoto T Tanaka 1, Yasuo Miki 1 2, Fumiaki Mori 1, Tomoya Kon 3, Tomonori Furukawa 4, Shuji Shimoyama 4, Yota Tatara 5, Taku Ozaki 6, Conceição Bettencourt 2 7, Thomas T Warner 2 7 8, Koichi Wakabayashi 1
Abstract:
...In this study, using early-stage multiple system atrophy mouse model and in vitro kinetic analysis, we investigated how intranasal and oral administration of trehalose can improve multiple system atrophy pathology and clinical symptoms. The multiple system atrophy model showed memory impairment at least four weeks after αSyn induction. Behavioural and physiological analyses showed that intranasal and oral administration of trehalose reversed memory impairments to near-normal levels. Notably, trehalose treatment reduced the amount of toxic αSyn and increased the aggregated form of αSyn in the multiple system atrophy model brain. In vitro kinetic analysis confirmed that trehalose accelerated the aggregate formation of αSyn. Based on our findings, we propose a novel strategy whereby accelerated αSyn aggregate formation leads to reduced exposure to toxic αSyn oligomers, particularly during the early phase of disease progression.
PMID: 39165481
Free Full-Text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334933/